ES2150018T3 - Secretagogas peptidomimeticas de bajo peso molecular liberadoras de la somatotrofina. - Google Patents

Secretagogas peptidomimeticas de bajo peso molecular liberadoras de la somatotrofina.

Info

Publication number
ES2150018T3
ES2150018T3 ES95940028T ES95940028T ES2150018T3 ES 2150018 T3 ES2150018 T3 ES 2150018T3 ES 95940028 T ES95940028 T ES 95940028T ES 95940028 T ES95940028 T ES 95940028T ES 2150018 T3 ES2150018 T3 ES 2150018T3
Authority
ES
Spain
Prior art keywords
somatotrophine
secretagogas
releasing
molecular weight
low molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95940028T
Other languages
English (en)
Inventor
Todd C Somers
Kathleen A Elias
Ross G Clark
Robert S Mcdowell
Mark S Stanley
John P Burnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2150018T3 publication Critical patent/ES2150018T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

LA PRESENTE INVENCION COMPRENDE PEPTIDOS/PEPTIDOMIMETICOS LIBERADORES DE LA HORMONA DEL CRECIMIENTO (GHRP) CAPACES DE CAUSAR LA LIBERACION DE LA HORMONA DEL CRECIMIENTO DE LA PITUITARIA. COMPOSICIONES QUE CONTIENEN LOS GHRP DE ESTA INVENCION SE UTILIZAN PARA PROMOVER EL CRECIMIENTO EN MAMIFEROS SOLOS O EN COMBINACION CON OTROS COMPUESTOS PROMOTORES DEL CRECIMIENTO, ESPECIALMENTE IGF-1. EN UN METODO DE ESTA INVENCION GHRP EN COMBINACION CON IGH-1 SE UTILIZAN PARA TRATAR DIABETES DE TIPO II. ARRIBA SE DISPONE UN COMPUESTO EJEMPLAR (1) DE ESTA INVENCION.
ES95940028T 1994-11-16 1995-11-16 Secretagogas peptidomimeticas de bajo peso molecular liberadoras de la somatotrofina. Expired - Lifetime ES2150018T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/340,767 US5798337A (en) 1994-11-16 1994-11-16 Low molecular weight peptidomimetic growth hormone secretagogues

Publications (1)

Publication Number Publication Date
ES2150018T3 true ES2150018T3 (es) 2000-11-16

Family

ID=23334858

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95940028T Expired - Lifetime ES2150018T3 (es) 1994-11-16 1995-11-16 Secretagogas peptidomimeticas de bajo peso molecular liberadoras de la somatotrofina.

Country Status (14)

Country Link
US (2) US5798337A (es)
EP (2) EP0792289B1 (es)
JP (1) JPH10509152A (es)
AT (2) ATE194626T1 (es)
CA (1) CA2203375A1 (es)
DE (2) DE69535491D1 (es)
DK (1) DK0792289T3 (es)
ES (1) ES2150018T3 (es)
GR (1) GR3034348T3 (es)
IL (1) IL115994A (es)
MX (1) MX9703550A (es)
PT (1) PT792289E (es)
WO (1) WO1996015148A2 (es)
ZA (1) ZA959757B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872100A (en) * 1990-05-11 1999-02-16 Deghenghi; Romano Peptides containing D-2-Alkyl-Tryptophan
EP0730578A4 (en) * 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES
BR9608909A (pt) * 1995-06-22 1999-03-02 Novo Nordisk As Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto
ZA966891B (en) * 1995-08-21 1998-02-16 Lilly Co Eli 2-acylaminopropanamines as growth hormone secretagogues.
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
AU715856B2 (en) * 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
SK285631B6 (sk) * 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
WO1998058950A1 (en) * 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6864250B1 (en) 1997-08-22 2005-03-08 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
IL137007A0 (en) 1998-01-16 2001-06-14 Novo Nordisk As Compounds with growth hormone releasing properties
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
US6025471A (en) * 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6468974B1 (en) 1998-08-14 2002-10-22 The Administrators Of The Tulane Educational Fund Compounds having growth hormone releasing activity
WO2000010565A1 (en) * 1998-08-18 2000-03-02 Eli Lilly And Company Growth hormone secretagogues
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
EP1158996A4 (en) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
US6828331B1 (en) * 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
JP2002523368A (ja) * 1999-02-19 2002-07-30 イーライ・リリー・アンド・カンパニー 成長ホルモン分泌促進薬
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU6936500A (en) * 1999-08-24 2001-03-19 Regents Of The University Of California, The Non-quinoline inhibitors of malaria parasites
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
HU229233B1 (en) 2000-06-13 2013-09-30 Aeterna Zentaris Gmbh Growth hormone secretagogues
EP1344773B1 (en) * 2000-06-13 2007-08-15 Zentaris GmbH Growth hormone secretagogues
AU2001286763C1 (en) * 2000-08-25 2006-03-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
US6579904B1 (en) * 2000-09-22 2003-06-17 K.E.R. Associates, Inc. Process for making betaine transition metal complexes for use in animal feed supplements and compositions thereof
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US7396846B2 (en) * 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
CA2492035A1 (en) 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
JP2005539091A (ja) 2002-08-23 2005-12-22 バラリゼーション−ラシェアシェイ ソサイテ エン コマンディテ アテローム性動脈硬化および高コレステロール血症の治療または予防における成長ホルモン放出ペプチド類
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2007523048A (ja) * 2003-08-06 2007-08-16 ガストロテック・ファルマ・アクティーゼルスカブ 分泌促進物質の使用
US20070037751A1 (en) * 2003-08-06 2007-02-15 Gastrotech Pharma A/S Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
EP2274978B1 (en) 2003-09-12 2015-05-20 Tercica, Inc. Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005063800A2 (en) * 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Peptide synthesis using decanting filter
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0603295D0 (en) * 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US8509284B2 (en) * 2009-06-08 2013-08-13 Harris Corporation Symbol duration dithering for secured chaotic communications
US8848909B2 (en) * 2009-07-22 2014-09-30 Harris Corporation Permission-based TDMA chaotic communication systems
SI2390284T1 (sl) 2010-05-28 2012-07-31 Omya Development Ag Postopek za izdelavo suspenzij mineralnih materialov z visoko vsebnostjo trdnih snovi
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR20170141730A (ko) * 2015-04-29 2017-12-26 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 EphA4의 리간드 결합 도메인을 표적화하는 신규한 EphA4 억제제
WO2016191865A1 (en) * 2015-05-29 2016-12-08 London Health Sciences Centre Research Inc. Peptidomimetics for imaging the ghrelin receptor
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
DE2655801C2 (de) * 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
US4228155A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) * 1979-03-30 1984-10-09 Frank A. Momany Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410513A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
EP0274259B1 (en) * 1986-12-19 1994-02-16 Sankyo Company Limited New renin-inhibitory oligopeptides, their preparaton and their use
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
AU628322B2 (en) * 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
EP0417165B1 (en) * 1988-05-11 1994-01-26 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
JP3130080B2 (ja) * 1990-12-27 2001-01-31 日清製粉株式会社 ペプチドおよびその製造方法
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5246920A (en) * 1992-06-15 1993-09-21 University Of South Florida Treatment of hyperprolactinemia
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5374721A (en) * 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1994011012A1 (en) * 1992-11-06 1994-05-26 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
CZ151495A3 (en) * 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof
PL314003A1 (en) * 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
SK56296A3 (en) * 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
EP0730578A4 (en) * 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES
EP0736039B1 (en) * 1993-12-23 2000-10-25 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1995034311A1 (en) * 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
CN1121413C (zh) * 1994-09-27 2003-09-17 R·德根格希 含d－2－烷基色氨酸的能促进生长激素释放的多肽化合物
UA55381C2 (uk) * 1995-01-27 2003-04-15 Ново Нордіск А/С Похідні пептиду (варіанти), що здатні вивільнювати гормон росту, фармацевтична композиція (варіанти), спосіб стимулювання вивільнення гормону росту з гіпофіза, способи підвищення швидкості і темпу росту та виробництва молока або вовни, спосіб лікування нездужань

Also Published As

Publication number Publication date
AU698676B2 (en) 1998-11-05
DE69518000T2 (de) 2000-12-07
EP0999220B1 (en) 2007-05-02
EP0792289B1 (en) 2000-07-12
DE69535491D1 (de) 2007-06-14
MX9703550A (es) 1997-08-30
WO1996015148A2 (en) 1996-05-23
CA2203375A1 (en) 1996-05-23
ATE361317T1 (de) 2007-05-15
PT792289E (pt) 2001-01-31
ATE194626T1 (de) 2000-07-15
EP0999220A2 (en) 2000-05-10
DK0792289T3 (da) 2000-10-30
WO1996015148A3 (en) 1996-11-14
AU4164496A (en) 1996-06-06
IL115994A0 (en) 1996-01-31
JPH10509152A (ja) 1998-09-08
GR3034348T3 (en) 2000-12-29
US6034216A (en) 2000-03-07
EP0999220A3 (en) 2000-09-20
ZA959757B (en) 1997-05-16
IL115994A (en) 2000-09-28
US5798337A (en) 1998-08-25
DE69518000D1 (de) 2000-08-17
EP0792289A1 (en) 1997-09-03

Similar Documents

Publication Publication Date Title
ES2150018T3 (es) Secretagogas peptidomimeticas de bajo peso molecular liberadoras de la somatotrofina.
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
DE3853384T2 (de) Peptid.
EA200000872A1 (ru) Способы лечения диабета с помощью пептидных аналогов инсулина
ES2071815T3 (es) Analogos de delecion de los peptidos conocidos como magaininas.
DK0896615T3 (da) Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator
AU1634288A (en) Cyclic anticoagulant peptides
IL86439A0 (en) Cyclic anticoagulant peptides
KR890003409A (ko) 점막 투여시 흡수 촉진제로서의 시클릭 펩티드
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
KR920701242A (ko) 환원된 비가역성 봄베신 길항제
DE69715910D1 (de) Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin-rezeptor interaktion
DE58908128D1 (de) Verbindungen zur Einführung einer SH-Gruppe in Tyrosin.
ES2129430T3 (es) Analogos superactivos del factor liberador de la hormona del crecimiento.
ATE163652T1 (de) Antikörper gegen das carboxy-terminale peptid des somatotropin-bindungsproteins der ratte
IL109978A0 (en) Ureins derived from alpha,omega-diamino acids and their preparation
ECSP961741A (es) Insulina de caneda sencilla con alta bioactividad (

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792289

Country of ref document: ES